When tumor presence was confirmed by bioluminescence, mice were treated with HER2-BsAb or control BsAb (20 ug i.v., 2 ×/wk × 3 weeks), in combination with PBMC (5 × 106 i.v., q wk × 2 weeks). This evidence concerns the gene ERBB2 and neoplasm.